Dechra Pharmaceutical plc (LON:DPH) has announced that the acquisition of the worldwide rights of the Osurnia product portfolio from Elanco Animal Health Incorporated has completed for a total consideration of USD135.0 million (£104.7 million)1. The addition of Osurnia to the Dechra dermatology portfolio will significantly enhance its presence in this key therapeutic area.
Osurnia is a long acting treatment for otitis externa (inflammation of the outer ear) in dogs. Osurnia was launched in 2014 and is currently approved in a number of countries including major markets, USA (2014), Europe (2014), Japan (2014), Canada (2015), Australia (2016) and New Zealand (2017). There are further submissions awaiting approval in Argentina, Thailand, Malaysia, South Korea and planned submissions in Venezuela (2021), Israel (2022), China (2024).
For the year ended 31 December 2018, the reported revenues for Osurnia were USD 31.2 million (£24.2 million) 1.
Ian Page, Dechra Pharmaceutical’s Chief Executive Officer commented:
“We are delighted to complete the acquisition of the worldwide rights to Osurnia. The addition of Osurnia will allow us to offer an extended range of solutions for veterinarians to manage otitis externa and offer the best treatment for the pet taking into consideration the veterinarians clinical preference and the owners’ lifestyle.”
1 Translated at USD 1.2896: GBP 1.0000 (closing rate on 27 July 2020)
